GLP-3 RTA vs IGF-1 LR3
GLP-3 RTA and IGF-1 LR3 come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do GLP-3 RTA and IGF-1 LR3 differ?
GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research; IGF-1 LR3 (Recombinant IGF-1 analog polypeptide) is catalogued under longevity & cellular research. Verve lists 5 reported research applications for GLP-3 RTA and 5 for IGF-1 LR3. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | GLP-3 RTA | IGF-1 LR3 |
|---|---|---|
| compound class | Synthetic triple-agonist peptide | Recombinant IGF-1 analog polypeptide |
| research area | weight & metabolic | longevity & cellular |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg · 20mg · 30mg | 1mg · 2x 1mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $142.99 | $93.49 |
| availability | in stock | out of stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is GLP-3 RTA and what is IGF-1 LR3?
GLP-3 RTA is classified as Synthetic triple-agonist peptide; IGF-1 LR3 as Recombinant IGF-1 analog polypeptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →IGF-1 LR3
Recombinant IGF-1 analog polypeptide
IGF-1 LR3 is Long R3 insulin-like growth factor 1, a recombinant analog of human IGF-1 carrying an arginine substitution at position 3 and a 13-residue N-terminal extension. Those two modifications are what define it: they substantially reduce its affinity for the insulin-like growth factor binding proteins (IGFBPs) that sequester native IGF-1 in culture systems.
full IGF-1 LR3 profile →Which research models is each compound studied in?
GLP-3 RTA sits in weight & metabolic research and IGF-1 LR3 in longevity & cellular research, so their listed models largely do not intersect. The table lists 5 reported research applications for GLP-3 RTA and 5 for IGF-1 LR3. Rows are per compound, not equivalences.
| GLP-3 RTA — reported research applications | IGF-1 LR3 — reported research applications |
|---|---|
| GLP-1, GIP, and glucagon receptor agonism research | IGF-1 receptor binding and signal-transduction research |
| cAMP and class B GPCR signaling research models | PI3K/Akt and MAPK pathway research in cellular models |
| Comparative single-, dual-, and triple-agonist pharmacology studies | Cell-culture media supplementation for proliferation research |
| Metabolic-pathway and nutrient-handling research models | IGFBP interaction and free-ligand availability studies |
| Peptide half-life, lipidation, and stability research | Comparative analog research against native IGF-1 |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for GLP-3 RTA and IGF-1 LR3?
GLP-3 RTA is listed from $142.99 and IGF-1 LR3 from $93.49. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
| IGF-1 LR3 | 1mg | $93.49 | out of stock |
| IGF-1 LR3 | 2x 1mg | $171.49 | out of stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about GLP-3 RTA and IGF-1 LR3
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
What is IGF-1 LR3?
IGF-1 LR3 is Long R3 insulin-like growth factor 1, a recombinant analog of human IGF-1 with an arginine substitution at position 3 and an N-terminal extension. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
How does IGF-1 LR3 differ from native IGF-1?
Its structural modifications reduce affinity for IGF binding proteins, so more of the ligand remains unbound in culture systems. Researchers use that property to control free-ligand availability in in-vitro models.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.